Department of Urology, Ishikawa Prefectural Central Hospital, Kanazawa 920-8530, Japan
Case Report
Enzalutamide for Primary Immune Prostate Cancer in Routine Clinical Practice: Results from a Rare Metastasis Study in Japan
Author(s): Kento Tomohisa*, Toma Abe, Ken Sota, Akiho Kato, Shigeo Sakurako, Tokuda Kaoru and Taka Yoshizawa
Introduction: The effectiveness and safety of romiplostim were evaluated by immune thrombocytopenia (ITP) phase (newly diagnosed/
persistent/chronic) at romiplostim initiation.
Methods: This is a post hoc analysis of a prospective, Japanese, multicentre, observational study in adults with ITP who received ≥ 1 dose of
romiplostim. Follow-up data were collected for ≤ 2 years. Outcomes included overall platelet response (≥ 1 platelet count ≥ 50 × 109/L at 2–24
weeks after romiplostim initiation) or durable platelet response (≥ 75% of measurements ≥ 50 × 109/L at 14–24 weeks) and adverse drug reactions
(ADRs), evaluated by ITP phase.
Results: Data from 96 patients were analysed (newly diagnosed, n =18; persistent, n=25; chronic, n=53). During the 2- to 24-week fol.. Read More»
DOI:
10.37421/2165-7920.2022.12.1534
Journal of Clinical Case Reports received 1295 citations as per Google Scholar report